ProQR Therapeutics (NASDAQ:PRQR) Stock Price Expected to Rise, HC Wainwright Analyst Says

ProQR Therapeutics (NASDAQ:PRQR) had its target price lifted by HC Wainwright from $5.00 to $10.00 in a report released on Friday,Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock.

Separately, Raymond James raised shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $6.00 to $14.00 in a research note on Tuesday, October 29th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $7.13.

ProQR Therapeutics Stock Up 5.0 %

Shares of PRQR opened at $3.96 on Friday. ProQR Therapeutics has a 52-week low of $1.18 and a 52-week high of $4.62. The stock has a fifty day simple moving average of $2.51 and a two-hundred day simple moving average of $2.11. The company has a market capitalization of $323.45 million, a PE ratio of -12.50 and a beta of 0.26.

Hedge Funds Weigh In On ProQR Therapeutics

Hedge funds have recently modified their holdings of the business. Ikarian Capital LLC raised its holdings in ProQR Therapeutics by 2.3% in the 1st quarter. Ikarian Capital LLC now owns 483,583 shares of the biopharmaceutical company’s stock valued at $1,098,000 after buying an additional 10,958 shares during the period. EP Wealth Advisors LLC acquired a new stake in shares of ProQR Therapeutics during the first quarter valued at about $26,000. OneDigital Investment Advisors LLC raised its stake in shares of ProQR Therapeutics by 37.0% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 15,550 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of ProQR Therapeutics by 120.1% in the 1st quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company’s stock worth $80,000 after acquiring an additional 19,100 shares during the last quarter. Finally, Acadian Asset Management LLC purchased a new position in shares of ProQR Therapeutics during the 1st quarter worth approximately $56,000. 32.65% of the stock is currently owned by hedge funds and other institutional investors.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).